Baillie Gifford & Co. Decreases Holdings in HUTCHISON CHINA/S (HCM)

Baillie Gifford & Co. cut its holdings in shares of HUTCHISON CHINA/S (NASDAQ:HCM) by 3.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 197,746 shares of the company’s stock after selling 6,917 shares during the quarter. Baillie Gifford & Co. owned 0.15% of HUTCHISON CHINA/S worth $6,365,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Bellevue Group AG raised its stake in shares of HUTCHISON CHINA/S by 10.0% during the 2nd quarter. Bellevue Group AG now owns 332,536 shares of the company’s stock worth $10,023,000 after purchasing an additional 30,116 shares in the last quarter. GSA Capital Partners LLP raised its stake in shares of HUTCHISON CHINA/S by 10.5% during the 2nd quarter. GSA Capital Partners LLP now owns 222,345 shares of the company’s stock worth $6,701,000 after purchasing an additional 21,077 shares in the last quarter. State of New Jersey Common Pension Fund D purchased a new stake in shares of HUTCHISON CHINA/S during the 2nd quarter worth about $2,651,000. Alps Advisors Inc. purchased a new stake in shares of HUTCHISON CHINA/S during the 2nd quarter worth about $5,785,000. Finally, Royal Bank of Canada purchased a new stake in shares of HUTCHISON CHINA/S during the 1st quarter worth about $199,000. Hedge funds and other institutional investors own 11.45% of the company’s stock.

HCM opened at $34.47 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.67 and a quick ratio of 4.55. HUTCHISON CHINA/S has a fifty-two week low of $25.76 and a fifty-two week high of $42.25. The stock has a market cap of $4.58 billion, a PE ratio of -156.68 and a beta of 0.01.

A number of equities research analysts have recently weighed in on the company. BidaskClub downgraded HUTCHISON CHINA/S from a “buy” rating to a “hold” rating in a research note on Thursday, August 23rd. Zacks Investment Research downgraded HUTCHISON CHINA/S from a “hold” rating to a “sell” rating in a research note on Tuesday, August 21st.

COPYRIGHT VIOLATION NOTICE: “Baillie Gifford & Co. Decreases Holdings in HUTCHISON CHINA/S (HCM)” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/12/03/baillie-gifford-co-decreases-holdings-in-hutchison-china-s-hcm.html.

HUTCHISON CHINA/S Profile

Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments.

Featured Story: What is a Roth IRA?

Want to see what other hedge funds are holding HCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HUTCHISON CHINA/S (NASDAQ:HCM).

Institutional Ownership by Quarter for HUTCHISON CHINA/S (NASDAQ:HCM)

Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply